Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2021 07:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
September 09, 2021 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first...
September 07, 2021 07:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
August 17, 2021 07:35 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
August 09, 2021 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 - - Licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets - ...
July 26, 2021 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
July 12, 2021 07:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
June 30, 2021 07:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA),...
September 10, 2020 18:00 ET | Source: Lyra Therapeutics

Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
September 03, 2020 16:05 ET | Source: Lyra Therapeutics

Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...